RedHill Biopharma Ltd. (RDHL)

8.19
0.19 2.38
NASDAQ : Health Technology
Prev Close 8.00
Open 8.13
Day Low/High 8.05 / 8.25
52 Wk Low/High 4.30 / 11.25
Volume 74.07K
Avg Volume 85.00K
Exchange NASDAQ
Shares Outstanding 21.27M
Market Cap 164.34M
EPS -2.60
P/E Ratio 30.77
Div & Yield N.A. (N.A)

Latest News

RedHill Biopharma Announces Two Oral Presentations On BEKINDA® 24 Mg For Acute Gastroenteritis At The SAEM 2018 Annual Meeting

RedHill Biopharma Announces Two Oral Presentations On BEKINDA® 24 Mg For Acute Gastroenteritis At The SAEM 2018 Annual Meeting
RedHill Biopharma Announces DDW 2018 Poster Of Distinction On Positive Phase II Results With BEKINDA® For IBS-D

RedHill Biopharma Announces DDW 2018 Poster Of Distinction On Positive Phase II Results With BEKINDA® For IBS-D
RedHill Biopharma To Present At H.C. Wainwright Annual Global Life Sciences Conference

RedHill Biopharma To Present At H.C. Wainwright Annual Global Life Sciences Conference

RedHill Biopharma Announces Poster Presentation On New Potential Therapeutic Applications Of RHB-107 At The AACR 2018 Annual Meeting

RedHill Biopharma Announces Poster Presentation On New Potential Therapeutic Applications Of RHB-107 At The AACR 2018 Annual Meeting

RedHill Biopharma Provides Fourth Quarter And Full-Year 2017 Investor Update

RedHill Biopharma Provides Fourth Quarter And Full-Year 2017 Investor Update

RedHill Biopharma To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call On February 22, 2018

RedHill Biopharma To Host Fourth Quarter And Full-Year 2017 Financial Results Conference Call On February 22, 2018

RedHill Biopharma To Present At BIO CEO & Investor Conference

RedHill Biopharma To Present At BIO CEO & Investor Conference

RedHill Biopharma And Express Scripts Subsidiary Inside Rx Add EnteraGam® To Savings Program For Uninsured Or Underinsured Patients

RedHill Biopharma And Express Scripts Subsidiary Inside Rx Add EnteraGam® To Savings Program For Uninsured Or Underinsured Patients

RedHill Biopharma Announces Final Results From Phase II Study With BEKINDA® For IBS-D

RedHill Biopharma Announces Final Results From Phase II Study With BEKINDA® For IBS-D

RedHill Biopharma Announces Initiation Of Phase IIa Study With ABC294640 (YELIVA®) For Cholangiocarcinoma At Mayo Clinic And MD Anderson

RedHill Biopharma Announces Initiation Of Phase IIa Study With ABC294640 (YELIVA®) For Cholangiocarcinoma At Mayo Clinic And MD Anderson

RedHill Biopharma Provides 2017 Year-End Business Update

RedHill Biopharma Provides 2017 Year-End Business Update

RedHill Biopharma Announces Closing Of Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Closing Of Public Offering Of Its American Depositary Shares

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Reports 2017 Third Quarter Financial Results

RedHill Biopharma Announces Last Patient Enrolled In The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Announces Last Patient Enrolled In The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Prices Public Offering Of Its American Depositary Shares

RedHill Biopharma Prices Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Proposed Public Offering Of Its American Depositary Shares

RedHill Biopharma Announces Proposed Public Offering Of Its American Depositary Shares

RedHill Biopharma To Host Third Quarter 2017 Financial Results Conference Call On November 13, 2017

RedHill Biopharma To Host Third Quarter 2017 Financial Results Conference Call On November 13, 2017

RedHill Biopharma Announces EnteraGam® Poster Presentation At The ISPOR 20th Annual European Congress

RedHill Biopharma Announces EnteraGam® Poster Presentation At The ISPOR 20th Annual European Congress

RedHill Biopharma And IntelGenx Submit New Drug Application To FDA For RIZAPORT® For Migraines

RedHill Biopharma And IntelGenx Submit New Drug Application To FDA For RIZAPORT® For Migraines

RedHill Biopharma To Present At The BIO-Europe 2017 Conference

RedHill Biopharma To Present At The BIO-Europe 2017 Conference

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering RHB-104

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering RHB-104

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

Celgene Down After Pulling Plug on Crohn's Disease Drug Study -- Biotech Movers

The Summit, N.J.-based firm said Thursday that it was discontinuing the GED-0301 (mongersen) Phase 3 Revolve study in Crohn's disease and the extension trial.

RedHill Biopharma Receives FDA Orphan Drug Designation For MESUPRON For Pancreatic Cancer

RedHill Biopharma Receives FDA Orphan Drug Designation For MESUPRON For Pancreatic Cancer

RedHill Biopharma Announces Poster Presentation At The 2017 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference

RedHill Biopharma Announces Poster Presentation At The 2017 AACR-NCI-EORTC Molecular Targets And Cancer Therapeutics Conference

RedHill Biopharma To Present At The BioNetwork 2017 Partnering Summit

RedHill Biopharma To Present At The BioNetwork 2017 Partnering Summit

RedHill Biopharma Announces Positive Top-Line Results From Phase II Study Of BEKINDA® In Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

RedHill Biopharma Announces Positive Top-Line Results From Phase II Study Of BEKINDA® In Patients With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

RedHill Biopharma Accelerates RHB-104 Phase III Study In Crohn's Disease With Top-Line Results Expected Mid-2018

RedHill Biopharma Accelerates RHB-104 Phase III Study In Crohn's Disease With Top-Line Results Expected Mid-2018

RedHill Biopharma To Announce Top-Line Results From BEKINDA® 12 Mg Phase II Study For IBS-D on October 3rd, 2017

RedHill Biopharma To Announce Top-Line Results From BEKINDA® 12 Mg Phase II Study For IBS-D on October 3rd, 2017

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering Its Combination Therapy For Hard-to-Treat Cancers

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering Its Combination Therapy For Hard-to-Treat Cancers

RedHill Biopharma To Present At The Cantor Fitzgerald Global Healthcare Conference

RedHill Biopharma To Present At The Cantor Fitzgerald Global Healthcare Conference

Load More
Quant Rating on 4:00 PM EDT 6/18/2018

D-

(Sell)

From Our Partners

Redhill (RDHL) Analyst And Investor Webcast On RHB-104 For Crohn's Disease - Slideshow
SeekingAlpha

Redhill up 11% on Q1 results
SeekingAlpha

3 Things In Biotech, May 7: Novartis Thyroid Breakout, Redhill's Stomach Bugs, Intra-Cellular Update On Schizoid Drugs
SeekingAlpha

Redhill EPS of -$0.05
SeekingAlpha

OrphoMed's lead candidate Fast Track'd for IBS-D
SeekingAlpha

Redhill (RDHL) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
SeekingAlpha

Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
SeekingAlpha

RedHill Biopharma provides semi-annual business update
SeekingAlpha

Key events next week - healthcare
SeekingAlpha

RedHill Biopharma announces Bekinda presentations in acute gastroenteritis at SAEM 2018
SeekingAlpha

RedHill Biopharma reports Q4 results
SeekingAlpha

Redhill EPS of -$0.05
SeekingAlpha

Redhill (RDHL) Presents At BIO CEO & Investor Conference - Slideshow
SeekingAlpha

Key events next week - healthcare
SeekingAlpha

RedHill Biopharma (RDHL) in Focus: Stock Moves 10.2% Higher
Zacks
TheStreet Quant Rating: D- (Sell)

Get the (RDHL)
Report Here

Free Reports

Watchlist

Trending
Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level
9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019
Global Gloom: Cramer's 'Mad Money' Recap (Monday 6/18/18)